Email Alert | RSS    帮助

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (2): 91-94.doi: 10.3969/j.issn.1000-6621.2020.02.003

所属专题: 标准、共识、指南

• 专论 • 上一篇    下一篇



  1. 200433 同济大学附属上海市肺科医院结核病临床研究中心 上海市结核病(肺)重点实验室
  • 收稿日期:2019-12-21 出版日期:2020-02-10 发布日期:2020-02-19
  • 通信作者: 范琳,肖和平;

Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus

FAN Lin(),LIU Yi-dian,XIAO He-ping()   

  1. Shanghai Pulmonary Hospital, Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Tongji University School of Medicine, Shanghai 200433,China
  • Received:2019-12-21 Online:2020-02-10 Published:2020-02-19
  • Contact: Lin FAN,He-ping XIAO;



关键词: 结核,抗多种药物性, 利福平, 总结性报告(主题), 指南, 评论


Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis (2019) (abbreviated as “Guidelines 2019”) and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment (2019 edition) and compared with WHO guidelines, provided the ideas from the elaboration on drug groups divided, implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians.

Key words: Tuberculosis,multidrug-resistant, Rifampin, Consensus development conferences as topic, Guidebooks, Comment